Vera Therapeutics Will Present Kidney Study Results
Vera Therapeutics is set to share new clinical trial data at ASN Kidney Week in Denver this October.
Updated on Oct. 2, 2026 in Asthma
Live Poll
Do you trust that pharmaceutical patient support programs sufficiently lower costs for patients needing specialty treatments?
Vera Therapeutics will deliver five abstract presentations at ASN Kidney Week 2026, which takes place in Denver from October 22 to 25. The schedule includes a featured late-breaking oral presentation detailing final efficacy results from the ORIGIN 3 trial.
Why it matters
The presentations aim to clarify the clinical impact of TRUTAKNA, a BAFF and APRIL inhibitor developed to address the root causes of IgA nephropathy. Demonstrating efficacy is a critical step for the company as it seeks to confirm clinical benefits in autoimmune kidney disease treatment.
In clinical trials, TRUTAKNA patients experienced an infection rate of 32% compared to 28% for those on a placebo. The drug is administered via a 150 mg once-weekly autoinjector.
The players
Vera Therapeutics
This Brisbane, California-based biotechnology company focuses on developing treatments for immunological and inflammatory diseases.
The details
TRUTAKNA functions as a soluble recombinant fusion protein that binds to BAFF and APRIL cytokines, which are key to the B cell activity that drives IgA nephropathy. Along with the ORIGIN 3 trial results, Vera Therapeutics will present interim findings from the PIONEER trial during the Denver conference.
Timeline
October 22, 2026: The ORIGIN 3 trial oral presentation occurs.
October 22-25, 2026: ASN Kidney Week 2026 takes place in Denver.
October 24, 2026: PIONEER trial and other research posters are presented.
The Big Picture
The upcoming presentations follow the established industry pattern of using the annual ASN Kidney Week 2026 conference to share pivotal trial results. This event serves as a central venue for researchers to influence the trajectory of nephrology treatment standards.
The results will provide medical professionals with a clearer understanding of TRUTAKNA's safety profile and efficacy for managing autoimmune kidney conditions. Patients should consult their care team regarding how these findings might influence future treatment options.
The takeaway
Vera Therapeutics is focusing on the efficacy of its BAFF and APRIL inhibitor to address complex kidney disease. These results will be vital for determining the long-term clinical role of the drug in treating IgA nephropathy.
Further reading
Learn more about the latest research in the Asthma section.
Live Poll
Do you trust that pharmaceutical patient support programs sufficiently lower costs for patients needing specialty treatments?
